Low-Dose Dimethyl Sulfoxide Suppresses Androgen Receptor and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer Cells

    August 2025 in “ Therapeutics ”
    Namrata Khurana, Hogyoung Kim, Talal W. Khan, Shohreh Kahhal, Amar Bukvic, Asim B. Abdel‐Mageed, Debasis Mondal, Suresh C. Sikka
    New to DMSO? There is a guide in the encyclopedia. Read the guide →
    Studysummary In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study demonstrates that low-dose dimethyl sulfoxide (DMSO) effectively suppresses androgen receptor (AR) and its splice variant AR-V7 in castration-resistant prostate cancer (CRPC) cells, specifically in 22Rv1 and C4-2B cell lines. DMSO showed a dose-dependent inhibitory effect on AR expression, with significant suppression of AR-V7 at concentrations as low as 0.5% and AR-FL at 2.5%. Additionally, DMSO reduced cell migration and exhibited antiproliferative and antimetastatic effects without significant cytotoxicity. The findings suggest that low-dose DMSO could be a safe and effective treatment option for CRPC, potentially enhancing the efficacy of conventional therapies.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results